Martin Filipits

TL;DR: Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ER CC1-positive tumors do not.

TL;DR: A gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor–positive, HER2-negative breast cancer treated with adjuvant endocrine therapy is developed and validated.

TL;DR: TILs and PD-L1 expression are detectable in the majority of glioblastoma samples but are not related to outcome, and a clinical study with specific immune checkpoint inhibitors seems to be warranted in gliOBlastoma.

TL;DR: It was found that none of the 16 antibodies could distinguish among the four ERCC1 protein isoforms, whereas only one isoform produced a protein that had full capacities for nucleotide excision repair and cisplatin resistance.

TL;DR: The results of the primary analysis constitute Level 1 evidence for clinical validity of the PAM50 test for predicting the risk of DR in postmenopausal women with ER+ EBC, and a 10-year metastasis risk of <3.5% makes it unlikely that additional chemotherapy would improve this outcome.